 xxxd2855xxx : a novel multitargeted  xxxg2198xxx  inhibitor.   xxxd2855xxx  ( xxxd2855xxx ) is a second-generation multitargeted  xxxg2198xxx  inhibitor against  xxxg2413xxx  receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. preclinical evaluation has revealed excellent antiangiogenic and antitumor activity, and synergism was observed in combination with chemotherapeutic drugs. significant antitumor activity was found in animal models of a variety of tumors, accompanied by desirable pharmacokinetics and oral bioavailability. phase i clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. ongoing trials are further evaluating  xxxd2855xxx  in a variety of malignancies.